article thumbnail

Gepirone

New Drug Approvals

5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. However, in 2012 it once again failed to convince the FDA of its qualities for treating anxiety and depression. [5] Jump up to: a b Fabre LF, Clayton AH, Smith LC, Goldstein I, Derogatis LR (March 2012).

FDA
article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

After their clinical results, their technology was licensed to Juno Therapeutics (later acquired by Bristol Myers Squibb.) In 2012, the University of Pennsylvania team and Novartis launched a collaboration to further develop the technology, which led to the FDA approval for the first commercial CAR T-cell therapy in 2017.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Obesity care gets personalised: tailoring therapies with Phenomix

Drug Target Review

Prior to founding Naia, Mark served as CEO of GenturaDx until its successful sale to Luminex Corporation in 2012. During his career, Mark has negotiated and managed six M&A transactions, raised more than half a billion dollars in equity and debt financings, and negotiated numerous licensing agreements.

article thumbnail

Vamorolone

New Drug Approvals

2012, 23, 821−828. (73) 2012, 23, 821−828. .; Damsker, J.; Nagaraju, K.; McCall, J. Connor, E. Novel approaches to corticosteroid treatment in Duchennemusculardystrophy.Phys.Med.Rehabil. 73) Singh, A.; Schaeffer, E. Reilly, C. Vertebral fractures in Duchenne muscular dystrophy patients managed with Deflazacort. 2018, 38, 320−324. (74)

FDA
article thumbnail

Landiolol

New Drug Approvals

Sakamoto A, Kitakaze M, Takamoto S, Namiki A, Kasanuki H, Hosoda S (2012). . “Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial” The Journal of Thoracic and Cardiovascular Surgery. 141 (6): 147887. doi : 10.1016/j.jtcvs.2010.10.045. 2010.10.045.

FDA
article thumbnail

Private equity firms back PCI Pharma in bet on drug production

BioPharma Drive: Drug Pricing

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Bain Capital, Kohlberg and Mubadala joined to invest in biopharmaceutical CDMO PCI Pharma on July 14, 2025. Frazier Healthcare Partners acquired it from Catalent Pharma in 2012 and sold a majority stake to Partners Group four years later.

article thumbnail

Moderate Image Uploads with AI/GenAI & AWS Rekognition

Perficient: Drug Development

By using that, not only can you make your business site compliant, but it also saves you a lot of cost, as you must pay only for what you use, without minimum fees, licenses, or upfront commitments. AWS Rekognition Content moderation can detect inappropriate or unwanted content and provide levels for the images.